Literature DB >> 7911582

Reduction of burn injury by inhibiting CD18-mediated leukocyte adherence in rabbits.

L P Bucky1, N B Vedder, H Z Hong, H P Ehrlich, R K Winn, J M Harlan, J W May.   

Abstract

The progressive nature of dermal ischemia and subsequent tissue destruction within the "zone of stasis" is a central focus in burn research. To examine the role of neutrophils and neutrophil adherence within the zone of stasis, we utilized the monoclonal antibody (MAb) 60.3, directed to the human leukocyte adherence glycoprotein CD18 to block neutrophil adherence to endothelium and intravascular aggregation in a rabbit model of partial-thickness burn. Burns were created by applying an 80 degrees C brass template to the dorsal rabbit skin for 5 or 10 seconds. Animals treated with MAb 60.3 thirty minutes following a 5-second burn had less edema, thinner eschar, and earlier elevation of the eschar than control animals. Histologic analysis revealed an eightfold increase in live hair follicles (p < 0.05) and 43 percent greater reepithelialization at 8 days (p < 0.05) and a 15 percent reduction in burn surface area at 24 hours (p < 0.0001) in the antibody-treated group. There was no significant difference between treatment and control groups exposed to 10-second burns. We conclude that neutrophils and increased neutrophil adherence play important roles in the progressive tissue destruction within the zone of stasis in burns. Furthermore, moderate burn injury may be significantly attenuated by blocking neutrophil adherence functions with a CD18 MAb.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7911582     DOI: 10.1097/00006534-199406000-00021

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  8 in total

Review 1.  Novel pharmacotherapy for burn wounds: what are the advancements.

Authors:  Michael R Hamblin
Journal:  Expert Opin Pharmacother       Date:  2018-12-05       Impact factor: 3.889

2.  The efficacy of recombinant human activated protein C (rhAPC) vs antithrombin III (at III) vs heparin, in the healing process of partial-thickness burns: a comparative study.

Authors:  O Kritikos; M Tsagarakis; D Tsoutsos; C Kittas; V Gorgoulis; A Papalois; A Giannopoulos; G Kakiopoulos; O Papadopoulos
Journal:  Ann Burns Fire Disasters       Date:  2012-06-30

Review 3.  Current concepts on burn wound conversion-A review of recent advances in understanding the secondary progressions of burns.

Authors:  Ara A Salibian; Angelica Tan Del Rosario; Lucio De Almeida Moura Severo; Long Nguyen; Derek A Banyard; Jason D Toranto; Gregory R D Evans; Alan D Widgerow
Journal:  Burns       Date:  2016-01-17       Impact factor: 2.744

4.  Reduction of burn progression with topical delivery of (antitumor necrosis factor-α)-hyaluronic acid conjugates.

Authors:  Liang Tso Sun; Emily Friedrich; Joshua L Heuslein; Rachel E Pferdehirt; Nicole M Dangelo; Shanmugasundaram Natesan; Robert J Christy; Newell R Washburn
Journal:  Wound Repair Regen       Date:  2012-06-19       Impact factor: 3.617

5.  Molecular imbalance mechanism of skin and blood leucocytes in severe burn patients at different burn times.

Authors:  Anru Liang; Fukui Qiu; Fangxiao Wu; Jiang Ruan; Lijuan Zhu; Yongxian Rong; Junjun Li
Journal:  Ann Transl Med       Date:  2022-09

6.  Targeted disruption of the galanin gene attenuates inflammatory responses in murine skin.

Authors:  Sabine M Schmidhuber; Anna Starr; David Wynick; Barbara Kofler; Susan D Brain
Journal:  J Mol Neurosci       Date:  2007-11-13       Impact factor: 3.444

7.  Management of an acute thermal injury with subatmospheric pressure.

Authors:  Joseph A Molnar; Jordan L Simpson; Denise M Voignier; Michael J Morykwas; Louis C Argenta
Journal:  J Burns Wounds       Date:  2005-03-24

8.  Dermal Nanoemulsion Treatment Reduces Burn Wound Conversion and Improves Skin Healing in a Porcine Model of Thermal Burn Injury.

Authors:  Vladislav A Dolgachev; Susan Ciotti; Emma Liechty; Benjamin Levi; Stewart C Wang; James R Baker; Mark R Hemmila
Journal:  J Burn Care Res       Date:  2021-11-24       Impact factor: 1.819

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.